PetCaseFinder

Peer-reviewed veterinary case report

Gastrin levels in dogs with primary hyperparathyroidism

By Vose, Julieann et al.Ā·Published in Journal of veterinary internal medicineĀ·2024Ā·Department of Small Animal Clinical Sciences, United StatesĀ·View original on PubMed →

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Serum gastrin concentrations in dogs with primary hyperparathyroidism.

Species:
dog
Stomach & digestionDogs

Plain-English summary

A group of dogs with primary hyperparathyroidism (PHPT) were tested for high levels of a hormone called gastrin, which can cause gastrointestinal (GI) issues. Out of 151 dogs, 27 had elevated gastrin levels, but this was not linked to any noticeable GI symptoms. After treatment for PHPT, which successfully lowered calcium and parathyroid hormone levels, gastrin levels remained unchanged. This suggests that while some dogs with PHPT may have higher gastrin, it doesn't necessarily mean they will show GI problems.

People also search for: dog hyperparathyroidism symptoms Ā· dog high gastrin levels treatment Ā· dog calcium hormone issues

Abstract

BACKGROUND: Hypercalcemia has been associated with hypergastrinemia in humans. Hypergastrinemia could be responsible for gastrointestinal (GI) signs in dogs with primary hyperparathyroidism (PHPT). HYPOTHESIS/OBJECTIVES: (a) Determine whether hypergastrinemia occurs in dogs with PHPT, (b) assess for potential correlations among ionized calcium (iCa), parathyroid hormone (PTH), and serum gastrin concentrations, and (c) determine whether gastrin concentrations decrease after management of PHPT. ANIMALS: Phase 1: 151 client-owned dogs at the time of PHPT diagnosis, Phase 2: 24 dogs that underwent treatment for PHPT. METHODS: Dogs with azotemia, concurrent disease, or those receiving acid suppressants were excluded. Twenty-four treated dogs had baseline and repeat quantification of serum gastrin, PTH, and iCa concentrations 4&#x2009;weeks after treatment. The effect of treatment on gastrin, iCa, and PTH concentrations was assessed using Wilcoxon signed rank sum tests. Fisher exact testing was used to compare the proportion of dogs with hypergastrinemia in dogs with and without GI signs. RESULTS: Twenty-seven of 151 PHPT dogs (17.9%) had increased pre-treatment serum gastrin concentrations (median, 45.0&#x2009;ng/L; interquartile range [IQR], 20.0&#x2009;ng/L). Gastrin concentrations were not correlated with iCa (P&#x2009;=&#x2009;.92) or PTH (P&#x2009;=&#x2009;.60). Treatment of PHPT decreased PTH (P&#x2009;<&#x2009;.001) and iCa concentrations (P&#x2009;<&#x2009;.001), but not gastrin concentrations (P&#x2009;=&#x2009;.15). The proportion of dogs with hypergastrinemia with and without GI signs did not differ (P&#x2009;=&#x2009;1.00). CONCLUSIONS AND CLINICAL IMPORTANCE: Mild increases in serum gastrin concentrations may be seen in dogs with PHPT, but this finding is independent of the presence of GI signs.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/38031928/